Assess efficacy and safety of Omacor® 4g with statin treatment for lowering TG levels in subjects with type 2 Diabetes combined with hyperlipidemia
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
68
Bucheon St. Mary's Hospital
Bucheon-si, South Korea
The mean percent change of Triglyceride(TG)
Time frame: from baseline at week 16
The mean percent change of Total Cholesterol(TC)
Time frame: from baseline at week 16
The mean percent change of LDL-C
Time frame: from baseline at week 16
The mean percent change of HDL-C
Time frame: from baseline at week 16
The mean percent change of HBA1c
Time frame: from baseline at week 16
The mean percent change of FPG
Time frame: from baseline at week 16
The mean percent change of hs-CRP
Time frame: from baseline at week 16
The mean percent change of PAI-1
Time frame: from baseline at week 16
The mean percent change of Apolipoprotein A1
Time frame: from baseline at week 16
The mean percent change of apolipoprotein B
Time frame: from baseline at week 16
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.